Page last updated: 2024-09-04

cox 189 and rofecoxib

cox 189 has been researched along with rofecoxib in 16 studies

Compound Research Comparison

Studies
(cox 189)
Trials
(cox 189)
Recent Studies (post-2010)
(cox 189)
Studies
(rofecoxib)
Trials
(rofecoxib)
Recent Studies (post-2010) (rofecoxib)
16349471,914307163

Protein Interaction Comparison

ProteinTaxonomycox 189 (IC50)rofecoxib (IC50)
Prostaglandin G/H synthase 2 Bos taurus (cattle)0.43
Cytochrome c oxidase subunit 2Homo sapiens (human)1.51
Prostaglandin G/H synthase 1Ovis aries (sheep)0.5
Seed linoleate 13S-lipoxygenase-1Glycine max (soybean)0.5
Calpain-2 catalytic subunitHomo sapiens (human)0.02
Prostaglandin G/H synthase 1Homo sapiens (human)1.8
Prostaglandin G/H synthase 2Homo sapiens (human)0.3602
Prostaglandin G/H synthase 2 Rattus norvegicus (Norway rat)0.76
Prostaglandin G/H synthase 2Ovis aries (sheep)0.486
Prostaglandin G/H synthase 2Mus musculus (house mouse)0.036
Sodium-dependent serotonin transporterMacaca mulatta (Rhesus monkey)0.5

Research

Studies (16)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's10 (62.50)29.6817
2010's6 (37.50)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Fricke, J; Jayawardene, S; Kellstein, D; Ott, D1
Bitner, M; Gao, J; Hatfield, C; Kattenhorn, J; Kellstein, D1
Hochberg, MC1
Bishop-Bailey, D; Mitchell, JA; Vojnovic, I; Warner, TD1
Marwali, MR; Mehta, JL1
Deray, G; Montalescot, G; Sibilia, J1
Deray, G; Héloire, F; Valat, JP1
Fu, YF; Ni, J; Ren, J; Shu, YY; Tang, W; Wang, H; Wang, MW; Yang, YF; Zhong, XG; Zhu, YN; Zuo, JP1
Ashcroft, DM; Chen, LC1
Krammer, G; Stricker, K; Yu, S1
Chakraborti, AK; Garg, SK; Jadhavar, PS; Kumar, R; Motiwala, HF1
Elliott, WJ1
Honjo, H; Iwamoto, K; Uwai, Y1
Hu, RW; Li, HY; Li, JS; Miao, XP; Ouyang, Q; Zhang, Y1
Hansen, SH; Skonberg, C; Syed, M1

Reviews

8 review(s) available for cox 189 and rofecoxib

ArticleYear
COX-2 selective inhibitors in the treatment of arthritis: a rheumatologist perspective.
    Current topics in medicinal chemistry, 2005, Volume: 5, Issue:5

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cost-Benefit Analysis; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Etoricoxib; Humans; Isoxazoles; Lactones; Membrane Proteins; Organic Chemicals; Osteoarthritis; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Rheumatology; Sulfonamides; Sulfones; Treatment Outcome

2005
COX-2 inhibitors and cardiovascular risk. Inferences based on biology and clinical studies.
    Thrombosis and haemostasis, 2006, Volume: 96, Issue:4

    Topics: Animals; Blood Platelets; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Diclofenac; Drug Labeling; Endothelium, Vascular; Epoprostenol; Humans; Lactones; Platelet Aggregation; Product Surveillance, Postmarketing; Pyrazoles; Randomized Controlled Trials as Topic; Risk Assessment; Sulfonamides; Sulfones; Thromboxane A2

2006
[What do we know about the cardiovascular toxicity of the NSAIDs?].
    Presse medicale (Paris, France : 1983), 2006, Volume: 35, Issue:9 Spec No

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Case-Control Studies; Celecoxib; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Follow-Up Studies; Humans; Isoxazoles; Lactones; Meta-Analysis as Topic; Middle Aged; Naproxen; Pyrazoles; Randomized Controlled Trials as Topic; Risk Factors; Sulfonamides; Sulfones; Thrombosis; Time Factors

2006
[Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?].
    Presse medicale (Paris, France : 1983), 2006, Volume: 35, Issue:9 Spec No

    Topics: Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Case-Control Studies; Celecoxib; Cohort Studies; Cyclooxygenase 2 Inhibitors; Diclofenac; Edema; Heart Failure; Humans; Hypertension; Isoxazoles; Lactones; Meta-Analysis as Topic; Middle Aged; Odds Ratio; Placebos; Prospective Studies; Pyrazoles; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Risk Factors; Sulfonamides; Sulfones; Thrombosis; Time Factors

2006
Risk of myocardial infarction associated with selective COX-2 inhibitors: meta-analysis of randomised controlled trials.
    Pharmacoepidemiology and drug safety, 2007, Volume: 16, Issue:7

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Etoricoxib; Humans; Isoxazoles; Lactones; Models, Statistical; Myocardial Infarction; Naproxen; Odds Ratio; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Risk; Risk Factors; Sulfonamides; Sulfones

2007
Progress in COX-2 inhibitors: a journey so far.
    Current medicinal chemistry, 2010, Volume: 17, Issue:15

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Diclofenac; Heterocyclic Compounds; Lactones; Models, Molecular; Sulfones

2010
Do the blood pressure effects of nonsteroidal antiinflammatory drugs influence cardiovascular morbidity and mortality?
    Current hypertension reports, 2010, Volume: 12, Issue:4

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Humans; Hypertension; Isoxazoles; Lactones; Pyrazoles; Pyridines; Risk; Risk Factors; Sulfonamides; Sulfones

2010
Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease.
    The Cochrane database of systematic reviews, 2014, Oct-23, Issue:10

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Colitis, Ulcerative; Crohn Disease; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Humans; Isoxazoles; Lactones; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Safety-Based Drug Withdrawals; Sulfonamides; Sulfones

2014

Trials

3 trial(s) available for cox 189 and rofecoxib

ArticleYear
Analgesic efficacy of a single dose of lumiracoxib compared with rofecoxib, celecoxib and placebo in the treatment of post-operative dental pain.
    International journal of clinical practice, 2004, Volume: 58, Issue:3

    Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Female; Humans; Lactones; Male; Molar, Third; Organic Chemicals; Pain, Postoperative; Pyrazoles; Sulfonamides; Sulfones; Tooth Extraction; Treatment Outcome

2004
Efficacy and tolerability of lumiracoxib in the treatment of primary dysmenorrhoea.
    International journal of clinical practice, 2004, Volume: 58, Issue:4

    Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cross-Over Studies; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Drug Therapy, Combination; Dysmenorrhea; Female; Humans; Isoenzymes; Lactones; Membrane Proteins; Middle Aged; Organic Chemicals; Prostaglandin-Endoperoxide Synthases; Sulfones; Treatment Outcome

2004
A 6-week, multicentre, randomised, double-blind, double-dummy, active-controlled, clinical safety study of lumiracoxib and rofecoxib in osteoarthritis patients.
    BMC musculoskeletal disorders, 2008, Sep-08, Volume: 9

    Topics: Aged; Arthralgia; Blood Pressure; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Double-Blind Method; Edema; Europe; Female; Gastrointestinal Tract; Humans; Incidence; Kidney; Lactones; Longitudinal Studies; Male; Middle Aged; Osteoarthritis; Sulfones

2008

Other Studies

5 other study(ies) available for cox 189 and rofecoxib

ArticleYear
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
Influence of plasma protein on the potencies of inhibitors of cyclooxygenase-1 and -2.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2006, Volume: 20, Issue:3

    Topics: Aspirin; Blood Platelets; Blood Proteins; Calcimycin; Calcium; Celecoxib; Cell Line; Cerebrospinal Fluid Proteins; Cyclooxygenase 1; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Dinoprostone; Humans; Indomethacin; Ionophores; Lactones; Meloxicam; Naproxen; Organ Specificity; Organic Chemicals; Protein Binding; Pyrazoles; Sodium Salicylate; Sulfonamides; Sulfones; Synovial Fluid; Thiazines; Thiazoles; Thromboxane A2

2006
COX-2 inhibitors ameliorate experimental autoimmune encephalomyelitis through modulating IFN-gamma and IL-10 production by inhibiting T-bet expression.
    Journal of neuroimmunology, 2007, Volume: 186, Issue:1-2

    Topics: Animals; Cell Proliferation; Cyclooxygenase 2 Inhibitors; Diclofenac; Disease Models, Animal; Dose-Response Relationship, Drug; Encephalomyelitis, Autoimmune, Experimental; Female; Gene Expression Regulation; Interferon-gamma; Interleukin-10; Lactones; Lymphocyte Activation; Mice; Mice, Inbred C57BL; Sulfones; T-Box Domain Proteins; T-Lymphocytes; Time Factors

2007
Inhibitory effect of selective cyclooxygenase-2 inhibitor lumiracoxib on human organic anion transporters hOAT1 and hOAT3.
    Drug metabolism and pharmacokinetics, 2010, Volume: 25, Issue:5

    Topics: Animals; Binding, Competitive; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Estrone; Etoricoxib; Humans; Inhibitory Concentration 50; Isoxazoles; Kinetics; Lactones; Methotrexate; Oocytes; Organic Anion Transport Protein 1; Organic Anion Transporters, Sodium-Independent; p-Aminohippuric Acid; Pyrazoles; Pyridines; RNA, Complementary; Sulfonamides; Sulfones; Xenopus laevis

2010
Mitochondrial toxicity of selective COX-2 inhibitors via inhibition of oxidative phosphorylation (ATP synthesis) in rat liver mitochondria.
    Toxicology in vitro : an international journal published in association with BIBRA, 2016, Volume: 32

    Topics: Adenosine Triphosphate; Animals; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Isoxazoles; Lactones; Male; Mitochondria, Liver; Oxidative Phosphorylation; Pyridines; Rats, Sprague-Dawley; Sulfonamides; Sulfones

2016